

Marco Giorgio PAGGI

email: marco.paggi@

Tel.: 06.5266.2550; +

Dati Anagrafici

Affiliazione IRCCS - Istituto Nazionale Tumori "Regina Elena", Dip. Ricerca e Tecnologie Avanzate, Via Elío Chianesi 53 - 00144 Roma

Studi	7/1972	Maturità Classica, Napoli
	7/1978	Laurea in Medicina e Chirurgia, con lode, Napoli
	12/1978	Abilitazione alla professione di Medico-Chirurgo, Napoli
	6/1981	Specializzazione in Patologia Generale, Roma
	11/1989	Specializzazione in Farmacologia Clinica , Roma

Esperienza Professionale

1/1979 – 11/1982, Istituto Regina Elena, Roma, Borsista in Biochimica
12/1982 – 3/1990, CNR, Roma, Assegnista ex lege 285/77
5/1983 – 8/1984, The Johns Hopkins University, School of Medicine, Baltimore, MD, USA, Post-doctoral Fellow
12/1990 – a tutt'oggi, Istituto Nazionale Tumori "Regina Elena", Roma
Dirigente Medico
04/2016 – a tutt'oggi, Istituto Nazionale Tumori "Regina Elena", Roma, Responsabile Unità di Proteomica

Progetti di Ricerca Finanziati Dal 1986 responsabile di 16 progetti di ricerca finanziati da CNR, AIRC, Ministero della Salute e Istituto Regina Elena, Ricerca Corrente.

Incarichi e Riconoscimenti Scientifici

1995-2005: incarico di ricerca presso l'Istituto Tecnologie Biomediche CNR, Roma
2000: Vincitore del Premio Internazionale "Sebetia-Ter" per le Scienze Biomediche.

2000-2003: Incarico di *Mentor*, "Marie Curie Training Site".

Luglio 2002 ad oggi: *Adjunct Professor*, Center of Biotechnology, *Temple University*, Philadelphia, USA.

Attuali Linee di Ricerca Scientifica Ricerca sperimentale: Farmacologia sperimentale, Proteomica, Trasduzione del segnale

Ricerca traslazionale: Farmacologia clinica, Trial clinici glioblastoma multifome.

Attività di revisore Pubblicazioni Riviste internazionali e Agenzie di finanziamento nazionali e internazionali
Autore di 124 pubblicazioni su riviste internazionali (PubMed).

Citation overview (Novembre 2023):

- *h*-index Google Scholar = 46
- Citazioni > 6600

Pubblicazioni 2000-2023

1. Pace A, Lombardi G, Villani V, Benincasa D, Abbruzzese C, Cestonaro I, et al. Repurposing Chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated MGMT gene promoter: RACTAC, a Phase II multicenter single arm clinical trial. *medRxiv* (2023), 2023.02.21.23286088. doi: 10.1101/2023.02.21.23286088.
2. Persico M, Abbruzzese C, Matteoni S, Matarrese P, Campana AM, Villani V, et al. Tackling the Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma. *Cells* (2022), 11, (2), 263. doi: 10.3390/cells11020263.
3. Paggi MG. Obituary: Armando Felsani (1947-2022). *Cell Death Discov* (2022), 8, (1), 412. doi: 10.1038/s41420-022-01208-w.
4. Pace A, Lombardi G, Matteoni S, Villani V, Benincasa D, Abbruzzese C, et al. Ctni-12. Phase II Multicentric Italian Trial on Repositioning of the Antipsychotic Drug Chlorpromazine and Its Combination with Temozolomide in Mgmt Unmethylated Glioblastoma Patients: The Ractac Trial. *Neuro-Oncology* (2022), 24, (Supplement_7), vii72-vii72. doi: 10.1093/neuonc/noac209.278.
5. Lombardi G, Paggi MG, Matteoni S, Villani V, Benincasa D, Abbruzzese C, et al. Phase II multicentric Italian trial on repositioning of the antipsychotic drug chlorpromazine and its combination with temozolomide in patients with MGMT unmethylated glioblastoma: The RACTAC trial. *J Clin Oncol* (2022), 40, (16_suppl), TPS2073-TPS2073. doi: 10.1200/JCO.2022.40.16_suppl.TPS2073.
6. Basso J, Paggi MG, Fortuna A, Vitorino C, Vitorino R. Deciphering specific miRNAs in brain tumors: a 5-miRNA signature in glioblastoma. *Mol Genet Genomics* (2022), 297, (2), 507-521. doi: 10.1007/s00438-022-01866-6.
7. Abbruzzese C, Persico M, Matteoni S, Paggi MG. Molecular Biology in Glioblastoma Multiforme Treatment. *Cells* (2022), 11, (11), 1850. doi: 10.3390/cells11111850.
8. Matteoni S, Matarrese P, Ascione B, Ricci-Vitiani L, Pallini R, Villani V, et al. Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response. *J Exp Clin Cancer Res* (2021), 40, (1), 347. doi: 10.1186/s13046-021-02144-w.
9. Matteoni S, Matarrese P, Ascione B, Buccarelli M, Ricci-Vitiani L, Pallini R, et al. Anticancer Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism With Temozolomide in Restraining Human Glioblastoma Proliferation In Vitro. *Front Oncol* (2021), 11, 635472. doi: 10.3389/fonc.2021.635472.
10. Matarrese P, Vona R, Ascione B, Paggi MG, Mileo AM. Physical Interaction between HPV16E7 and the Actin-Binding Protein Gelsolin Regulates Epithelial-Mesenchymal Transition via HIPPO-YAP Axis. *Cancers (Basel)* (2021), 13, (2), 353. doi: 10.3390/cancers13020353.
11. Matteoni S, Abbruzzese C, Villani V, Malorni W, Pace A, Matarrese P, et al. The influence of patient sex on clinical approaches to malignant glioma. *Cancer Lett* (2020), 468, 41-47. doi: 10.1016/j.canlet.2019.10.012.
12. Ciliberto G, Mancini R, Paggi MG. Drug repurposing against COVID-19: focus on anticancer agents. *J Exp Clin Cancer Res* (2020), 39, (1), 86. doi: 10.1186/s13046-020-01590-2.

13. Abbruzzese C, Matteoni S, Persico M, Villani V, Paggi MG. Repurposing chlorpromazine in the treatment of glioblastoma multiforme: analysis of literature and forthcoming steps. *J Exp Clin Cancer Res* (2020), 39, (1), 26. doi: 10.1186/s13046-020-1534-z.
14. Matteoni S, Abbruzzese C, Matarrese P, De Luca G, Mileo AM, Miccadei S, et al. The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells. *J Exp Clin Cancer Res* (2019), 38, (1), 202. doi: 10.1186/s13046-019-1212-1.
15. Abbruzzese C, Matteoni S, Persico M, Ascione B, Schenone S, Musumeci F, et al. The small molecule SI113 hinders epithelial-to-mesenchymal transition and subverts cytoskeletal organization in human cancer cells. *J Cell Physiol* (2019), 234, (12), 22529-22542. doi: 10.1002/jcp.28816.
16. Abbruzzese C, Matteoni S, Signore M, Cardone L, Nath K, Glickson JD, et al. Drug repurposing for the treatment of glioblastoma multiforme. *J Exp Clin Cancer Res* (2017), 36, (1), 169. doi: 10.1186/s13046-017-0642-x.
17. Abbruzzese C, Catalogna G, Gallo E, di Martino S, Mileo AM, Carosi M, et al. The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme. *Oncotarget* (2017), 8, (67), 110743-110755. doi: 10.18632/oncotarget.22500.
18. Talarico C, Dattilo V, D'Antona L, Barone A, Amodio N, Belviso S, et al. SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. *Oncotarget* (2016), 7, (13), 15868-84. doi: 10.18632/oncotarget.7520.
19. Matarrese P, Abbruzzese C, Mileo AM, Vona R, Ascione B, Visca P, et al. Interaction between the human papillomavirus 16 E7 oncoprotein and gelsolin ignites cancer cell motility and invasiveness. *Oncotarget* (2016), 7, (32), 50972-50985. doi: 10.18632/oncotarget.8646.
20. Talarico C, D'Antona L, Scumaci D, Barone A, Gigliotti F, Fiumara CV, et al. Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy. *Oncotarget* (2015), 6, (35), 37511-25. doi: 10.18632/oncotarget.5527.
21. Mileo AM, Mattarocci S, Matarrese P, Anticoli S, Abbruzzese C, Catone S, et al. Hepatitis C virus core protein modulates pRb2/p130 expression in human hepatocellular carcinoma cell lines through promoter methylation. *J Exp Clin Cancer Res* (2015), 34, (1), 140. doi: 10.1186/s13046-015-0255-1.
22. D'Antona L, Amato R, Talarico C, Ortuso F, Menniti M, Dattilo V, et al. SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation. *Cell Physiol Biochem* (2015), 35, (5), 2006-18. doi: 10.1159/000374008.
23. Abbruzzese C, Diodoro MG, Sperduti I, Mileo AM, Pattaro G, De Salvo L, et al. Detection of phosphorylated insulin receptor in colorectal adenoma and adenocarcinoma: implications for prognosis and clinical outcome. *J Cell Physiol* (2015), 230, (3), 562-7. doi: 10.1002/jcp.24733.
24. Mattarocci S, Abbruzzese C, Mileo AM, Carosi M, Pescarmona E, Vico C, et al. Identification of pivotal cellular factors involved in HPV-induced dysplastic and

- neoplastic cervical pathologies. *J Cell Physiol* (2014), 229, (4), 463-70. doi: 10.1002/jcp.24465.
25. Mileo AM, Abbruzzese C, Vico C, Bellacchio E, Matarrese P, Ascione B, et al. The Human Papillomavirus-16 E7 oncoprotein exerts anti-apoptotic effects via its physical interaction with the actin-binding protein Gelsolin. *Carcinogenesis* (2013), 34, (10), 2424-2433. doi: bgt192 [pii];10.1093/carcin/bgt192 [doi].
 26. Bellacchio E, Paggi MG. Understanding the targeting of the RB family proteins by viral oncoproteins to defeat their oncogenic machinery. *J Cell Physiol* (2013), 228, (2), 285-91. doi: 10.1002/jcp.24137.
 27. Amato R, Scumaci D, D'Antona L, Iuliano R, Menniti M, Di Sanzo M, et al. Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells. *Oncogene* (2013), 32, (38), 4572-8. doi: 10.1038/onc.2012.470.
 28. R. LM, Caligiuri I, Maranta P, Lucchetti C, Esposito L, Paggi MG, et al. Androgen receptor serine 81 mediates Pin1 interaction and activity. *Cell Cycle* (2012), 11, (18), 3415-3420. doi: 21730 [pii];10.4161/cc.21730 [doi].
 29. D'Andrilli G, Bovicelli A, Paggi MG, Giordano A. New insights in endometrial carcinogenesis. *J Cell Physiol* (2012), 227, (7), 2842-6. doi: 10.1002/jcp.24016.
 30. Akl EA, Meerpohl JJ, Raad D, Piaggio G, Mattioni M, Paggi MG, et al. Effects of assessing the productivity of faculty in academic medical centres: a systematic review. *CMAJ* (2012), 184, (11), E602-12. doi: 10.1503/cmaj.111123.
 31. Abbruzzese C, Mattarocci S, Pizzuti L, Mileo AM, Visca P, Antoniani B, et al. Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas. *J Exp Clin Cancer Res* (2012), 31, (1), 4. doi: 10.1186/1756-9966-31-4.
 32. Campioni M, Severino A, Manente L, De Luca A, La Porta R, Vitiello A, et al. Identification of protein-protein interactions of human HtrA1. *Front Biosci (Elite Ed)* (2011), 3, 1493-9. doi: 350 [pii].
 33. Barba M, Mazza A, Guerriero C, Di Maio M, Romeo F, Maranta P, et al. Wasting lives: the effects of toxic waste exposure on health. The case of Campania, Southern Italy. *Cancer Biol Ther* (2011), 12, (2), 106-11. doi: 16910 [pii].
 34. Barba M, Felsani A, Rinaldi M, Giunta S, Malorni W, Paggi MG. Reducing the risk of overdiagnosis in lung cancer: a support from molecular biology. *J Cell Physiol* (2011), 226, (9), 2213-4. doi: 10.1002/jcp.22558.
 35. Accardi L, Dona MG, Mileo AM, Paggi MG, Federico A, Torreri P, et al. Retinoblastoma-independent antiproliferative activity of novel intracellular antibodies against the E7 oncoprotein in HPV 16-positive cells. *BMC cancer* (2011), 11, (1), 17. doi: 10.1186/1471-2407-11-17.
 36. Paggi MG, Vona R, Abbruzzese C, Malorni W. Gender-related disparities in non-small cell lung cancer. *Cancer Lett* (2010), 298, (1), 1-8. doi: 10.1016/j.canlet.2010.08.009.
 37. Matarrese P, Ascione B, Ciarlo L, Vona R, Leonetti C, Scarsella M, et al. Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study. *Mol Cancer* (2010), 9, (1), 207. doi: 10.1186/1476-4598-9-207.
 38. Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. *World J Stem Cells* (2010), 2, (1), 5-12. doi: 10.4252/wjsc.v2.i1.5.

39. Mileo AM, Abbruzzese C, Mattarocci S, Bellacchio E, Pisano P, Federico A, et al. Human papillomavirus-16 E7 interacts with glutathione S-transferase P1 and enhances its role in cell survival. *PLoS One* (2009), 4, (10), e7254. doi: 10.1371/journal.pone.0007254.
40. Mattarocci S, Abbruzzese C, Mileo AM, Visca P, Antoniani B, Alessandrini G, et al. Intracellular presence of insulin and its phosphorylated receptor in non-small cell lung cancer. *J Cell Physiol* (2009), 221, (3), 766-70. doi: 10.1002/jcp.21916.
41. Amato R, D'Antona L, Porciatti G, Agosti V, Menniti M, Rinaldo C, et al. Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. *J Mol Med (Berl)* (2009), 87, (12), 1221-39. doi: 10.1007/s00109-009-0525-5.
42. Maresca V, Flori E, Briganti S, Mastrofrancesco A, Fabbri C, Mileo AM, et al. Correlation between melanogenic and catalase activity in in vitro human melanocytes: a synergic strategy against oxidative stress. *Pigm Cell Melanoma R* (2008), 21, (2), 200-205. doi: 10.1111/j.1755-148X.2007.00432.x.
43. Bellacchio E, Paggi MG. Protease-mediated arsenic prodrug strategy in cancer and infectious diseases: a hypothesis for targeted activation. *J Cell Physiol* (2008), 214, (3), 681-6. doi: 10.1002/jcp.21261.
44. Severino A, Abbruzzese C, Manente L, Valderas AA, Mattarocci S, Federico A, et al. Human papillomavirus-16 E7 interacts with Siva-1 and modulates apoptosis in HaCaT human immortalized keratinocytes. *J Cell Physiol* (2007), 212, (1), 118-25. doi: 10.1002/jcp.21011.
45. Giovannetti A, Pierdominici M, Mazzetta F, Marziali M, Renzi C, Mileo AM, et al. Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. *J Immunol* (2007), 178, (6), 3932-43. doi: 10.1002/jcp.21011.
46. Giordano A, Bellacchio E, Bagella L, Paggi MG. Interaction Between the Cdk2/Cyclin A Complex and a Small Molecule Derived from the pRb2/p130 Spacer Domain: A Theoretical Model. *Cell Cycle* (2007), 6, (21), 2591-2593. doi: 10.1002/jcp.21011.
47. Felsani A, Mileo AM, Maresca V, Picardo M, Paggi MG. New technologies used in the study of human melanoma. *Int Rev Cytol* (2007), 261, 247-+. doi: 10.1016/S0074-7696(07)61006-7.
48. Bagella L, Sun A, Tonini T, Abbadessa G, Cottone G, Paggi MG, et al. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. *Oncogene* (2007), 26, (13), 1829-39. doi: 10.1038/sj.onc.1209987.
49. Mileo AM, Piombino E, Severino A, Tritarelli A, Paggi MG, Lombardi D. Multiple interference of the human papillomavirus-16 E7 oncoprotein with the functional role of the metastasis suppressor Nm23-H1 protein. *J Bioenerg Biomembr* (2006), 38, (3-4), 215-25. doi: 10.1007/s10863-006-9037-y.
50. Maresca V, Flori E, Cardinali G, Briganti S, Lombardi D, Mileo AM, et al. Ferritin light chain down-modulation generates depigmentation in human metastatic melanoma cells by influencing tyrosinase maturation. *J Cell Physiol* (2006), 206, (3), 843-8. doi: 10.1002/jcp.20543.
51. Felsani A, Mileo AM, Paggi MG. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. *Oncogene* (2006), 25, (38), 5277-85. doi: 10.1038/sj.onc.1209621.

52. Cottone G, Baldi A, Palescandolo E, Manente L, Penta R, Paggi MG, et al. Pkn is a novel partner of cyclin T2a in muscle differentiation. *J Cell Physiol* (2006), 207, (1), 232-7. doi: 10.1002/jcp.20566.
53. Noonan DM, Severino A, Morini M, Tritarelli A, Manente L, D'Agnano I, et al. In vitro and in vivo tumor growth inhibition by a p16-mimicking peptide in p16(INK4A)-defective, pRb-positive human melanoma cells. *J Cell Physiol* (2005), 202, (3), 922-928. doi:
54. Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, et al. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. *Clin Cancer Res* (2005), 11, (9), 3175-83. doi: 10.1158/1078-0432.CCR-04-0631.
55. Severino A, Baldi A, Cottone G, Han M, Sang N, Giordano A, et al. RACK1 is a functional target of the E1A oncoprotein. *J Cell Physiol* (2004), 199, (1), 134-9. doi: 10.1002/jcp.10448.
56. Paggi MG, Felsani A. Synthetic oligopeptides as G1 checkpoint modulators in cancer. *Logical Biol.* (2004), 4, (1), 68-74. doi:
57. De Luca A, De Falco M, Fedele V, Cobellis L, Mastrogiacomo A, Laforgia V, et al. The Serine Protease HtrA1 Is Upregulated in the Human Placenta During Pregnancy. *J.Histochem.Cytochem.* (2004), 52, (7), 885-892. doi:
58. De Luca A, De Falco M, De Luca L, Penta R, Shridhar V, Baldi F, et al. Pattern of expression of HtrA1 during mouse development. *J Histochem Cytochem* (2004), 52, (12), 1609-17. doi: 10.1369/jhc.4A6330.2004.
59. Baldi A, Santini D, Russo P, Catricala C, Amantea A, Picardo M, et al. Analysis of APAF-1 expression in human cutaneous melanoma progression. *Exp Dermatol* (2004), 13, (2), 93-7. doi: 10.1111/j.0906-6705.2004.00136.x.
60. Baldi A, De Falco M, De Luca L, Cottone G, Paggi MG, Nickoloff BJ, et al. Characterization of tissue specific expression of Notch-1 in human tissues. *Biol Cell* (2004), 96, (4), 303-11. doi: 10.1016/j.biolcel.2004.01.005.
61. Severino A, Felsani A, Giordano A, Paggi MG, Synthetic Oligopeptides as Cancer Cell Cycle Modulators. In *Cell Cycle Inhibitors in Cancer Therapy*, Giordano, A.; Soprano, K. J., Eds. Humana Press Inc: Totowa, NJ, 2003; pp 297-310.
62. Paggi MG, Felsani A, Giordano A. Growth control by the retinoblastoma gene family. *Methods Mol Biol* (2003), 222, 3-19. doi: 10.1385/1-59259-328-3:003.
63. Paggi MG, Catricala C, Amantea A, Picardo M, Natali PG, Baldi F, et al. SP-22 Analysis of APAF-1 Expression in Human Cutaneous Melanoma Progression. *Pigment Cell Res.* (2003), 16, (5), 589. doi:
64. Macaluso M, Paggi MG, Giordano A. Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. *Oncogene* (2003), 22, (42), 6472-8. doi: 10.1038/sj.onc.1206955.
65. Lavia P, Mileo AM, Giordano A, Paggi MG. Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. *Oncogene* (2003), 22, (42), 6508-16. doi: 10.1038/sj.onc.1206861.
66. De Luca A, Mangiacasale R, Severino A, Malquori L, Baldi A, Palena A, et al. E1A deregulates the centrosome cycle in a Ran GTPase-dependent manner. *Cancer Res* (2003), 63, (6), 1430-7. doi:

67. De Luca A, De Falco M, Severino A, Campioni M, Santini D, Baldi F, et al. Distribution of the serine protease HtrA1 in normal human tissues. *J Histochem Cytochem* (2003), 51, (10), 1279-84. doi: 10.1177/002215540305101004.
68. De Luca A, De Falco M, Baldi A, Paggi MG. Cyclin T: three forms for different roles in physiological and pathological functions. *J Cell Physiol* (2003), 194, (2), 101-7. doi: 10.1002/jcp.10196.
69. De Luca A, Baldi A, Russo P, Todisco A, Altucci L, Giardullo N, et al. Coexpression of *Helicobacter pylori*'s proteins CagA and HspB induces cell proliferation in AGS gastric epithelial cells, independently from the bacterial infection. *Cancer Res* (2003), 63, (19), 6350-6. doi:
70. Baldi A, Santini D, De Luca A, Paggi MG. cDNA array technology in melanoma: an overview. *J Cell Physiol* (2003), 196, (2), 219-23. doi: 10.1002/jcp.10255.
71. Baldi A, Battista T, De Luca A, Santini D, Rossiello L, Baldi F, et al. Identification of genes down-regulated during melanoma progression: a cDNA array study. *Exp Dermatol* (2003), 12, (2), 213-8. doi: 10.1034/j.1600-0625.2003.00026.x.
72. Baldi A, Groeger AM, Esposito V, Cassandro R, Tonini G, Battista T, et al. Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival. *Thorax* (2002), 57, (4), 353-6. doi: 10.1136/thorax.57.4.353.
73. Baldi A, De Luca A, Morini M, Battista T, Felsani A, Baldi F, et al. The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. *Oncogene* (2002), 21, (43), 6684-8. doi: 10.1038/sj.onc.1205911.
74. Sang N, Severino A, Russo P, Baldi A, Giordano A, Mileo AM, et al. RACK1 interacts with E1A and rescues E1A-induced yeast growth inhibition and mammalian cell apoptosis. *J Biol Chem* (2001), 276, (29), 27026-33. doi: 10.1074/jbc.M010346200.
75. Raschella G, Tanno B, Bonetto F, Negroni A, Amendola R, Paggi MG. Retinoblastoma family proteins induce differentiation and regulate B-myb expression in neuroblastoma cells. *Med Pediatr Oncol* (2001), 36, (1), 104-7. doi: 10.1002/1096-911X(20010101)36:1<104::AID-MPO1024>3.0.CO;2-9.
76. Paggi MG, Giordano A. Who Is the Boss in the Retinoblastoma Family? The Point of View of *Rb2/p130*, the Little Brother. *Cancer Res.* (2001), 61, (12), 4651-4654. doi:
77. Paggi MG, Bonetto F, Severino A, Baldi A, Battista T, Bucci F, et al. The retinoblastoma-related *Rb2/p130* gene is an effector downstream of AP-2 during neural differentiation. *Oncogene* (2001), 20, (20), 2570-8. doi: 10.1038/sj.onc.1204356.
78. Lombardi D, Palescandolo E, Giordano A, Paggi MG. Interplay between the antimetastatic nm23 and the retinoblastoma-related *Rb2/p130* genes in promoting neuronal differentiation of PC12 cells. *Cell Death Differ* (2001), 8, (5), 470-6. doi: 10.1038/sj.cdd.4400842.
79. De Luca A, Tosolini A, Russo P, Severino A, Baldi A, De Luca L, et al. Cyclin T2a gene maps on human chromosome 2q21. *J Histochem Cytochem* (2001), 49, (6), 693-8. doi: 10.1177/002215540104900603.

80. De Luca A, Russo P, Severino A, Baldi A, Battista T, Cavallotti I, et al. Pattern of expression of cyclin T1 in human tissues. *J Histochem Cytochem* (2001), 49, (6), 685-92. doi: 10.1177/002215540104900602.
81. Claudio PP, Cinti C, Paggi MG, Giordano A. Letters to the Editor. Reply. *Cancer Res.* (2001), 61, (15), 5952-5953. doi:
82. Baldi A, Santini D, Paggi MG. Association for Molecular Pathology: Sixth annual meeting in Denver, November 9-12, 2000. *J Cell Physiol* (2001), 188, (1), 139-42. doi: 10.1002/jcp.1096.
83. Baldi A, Santini D, Battista T, Dragonetti E, Ferranti G, Petitti T, et al. Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. *J Cell Biochem* (2001), 83, (3), 364-72. doi: 10.1002/jcb.1235.
84. Lombardi D, Lacombe ML, Paggi MG. nm23: unraveling its biological function in cell differentiation. *J Cell Physiol* (2000), 182, (2), 144-9. doi: 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.0.CO;2-6.
85. Cinti C, Claudio PP, Luca AD, Cuccurese M, Howard CM, D'Esposito M, et al. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line. *Oncogene* (2000), 19, (44), 5098-105. doi: 10.1038/sj.onc.1203848.

}